Adaptimmune

  • Home
  • Our Company
    • Overview arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
  • Products
  • Pipeline
    • Overview arrow_forward
    • Afami-cel arrow_forward
    • Lete-cel arrow_forward
    • Uza-cel arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clinical Trials arrow_forward
    • Videos arrow_forward
  • Clinical Trials
    • Overview arrow_forward
    • Expanded Access Policy arrow_forward
  • Investors & Media
    • Overview arrow_forward
    • News Center arrow_forward
    • Financial Info and Governance arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • US Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News Center
    • Media Resources
    • Corporate Presentations
    • Press Releases
    • Publications
    • Events
    • Email Alerts
  • Financial Info and Governance
    • General Meeting (merger)
    • Company Information
    • Leadership Team
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Annual Shareholder Meeting
    • FAQ
    • Contacts
    • Adaptimmune Ltd Report
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • News Center

  • Media Resources
  • Corporate Presentations
  • Press Releases
  • Publications
  • Events
  • Email Alerts
Feb 07, 2019 8:00am EST

Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019

Jan 07, 2019 7:30am EST

Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews

Dec 12, 2018 8:30am EST

Adaptimmune Announces that Gwen Binder will leave in January 2019

Nov 06, 2018 7:30am EST

Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update

Oct 25, 2018 4:30pm EDT

Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018

Oct 20, 2018 10:45am EDT

Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress

Oct 08, 2018 6:10pm EDT

Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress

Sep 07, 2018 1:14pm EDT

Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares

Sep 05, 2018 7:30am EDT

Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares

Aug 15, 2018 7:30am EDT

Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort

RSS
  • Prev
  • 1...
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • ...29
  • Next
Adaptimmune
Disclosures Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms Cookie Policy Manage Cookie Preferences
Linedin Twitter Youtube
© 2025 Adaptimmune. All Rights Reserved.